ArticleImmuno-oncology technology2025

Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers.

J Palomero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.